Evidence map›Paper›PMID 39558658›Full record

ArticleFuture oncology (London, England)2024

The application of QCT in the prognostic assessment of mCRC undergoing first-line treatment based on bevacizumab.

Xudong Liu, Shusheng Wu, Wenxi Dang, Hao Shen, Mingjie Sun, Yaolin Chen, Zhihua Zhang, Mengge Li, Zhirun Cai, Haoyu Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xudong LiuGraduate School, Wannan Medical College, Wuhu, Anhui, China.
Shusheng WuGastrointestinal Oncology Department, The First Affiliated Hospital of USTC West District, Hefei, Anhui, China.
Wenxi DangGraduate School, Anhui Medical University, Hefei, Anhui, China.
Hao ShenGraduate School, Anhui Medical University, Hefei, Anhui, China.
Mingjie SunGraduate School, Wannan Medical College, Wuhu, Anhui, China.
Yaolin ChenGraduate School, Wannan Medical College, Wuhu, Anhui, China.
Zhihua ZhangGraduate School, University of Science and Technology of China, Hefei, Anhui, China.
Mengge LiGastrointestinal Oncology Department, The First Affiliated Hospital of USTC West District, Hefei, Anhui, China.
Zhirun CaiGraduate School, Wannan Medical College, Wuhu, Anhui, China.
Haoyu WangGraduate School, University of Science and Technology of China, Hefei, Anhui, China.
Fei GaoGastrointestinal Oncology Department, The First Affiliated Hospital of USTC West District, Hefei, Anhui, China.
Yifu HeGastrointestinal Oncology Department, The First Affiliated Hospital of USTC West District, Hefei, Anhui, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area. MATERIALS &

methodsA total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment.

resultsTreatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis.

conclusionA predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabColorectal NeoplasmsTomography, X-Ray ComputedAdultAgedBody CompositionFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalBevacizumabbody componentschemotherapynomogramTargeted therapyvisceral fat area

Identifiers

PMID39558658
PMCPMC11776858

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.